Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

Completed · Phase 2

Conditions studied: Scalp Psoriasis

In brief

An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis

Key facts

Study ID

NCT02933502

Run by

Sun Pharmaceutical Industries, Inc.

People needed

3

Starts

2016-07-11

Expected to finish

2018-01-02

Last updated by the study team

2018-12-10

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or non-pregnant, non-lactating females 12-17 years of age.

You may not qualify if…

• Females who are pregnant, nursing, planning to become pregnant during the duration of the study, or if of child-bearing potential and sexually active and not prepared to use appropriate contraceptive methods to avoid pregnancy.

Where it is running

• Taro Pharmaceuticals USA Inc. — Hawthorne, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.